Domenico Russo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Domenico Russo has a total of 245 co-authors. Here are the top co-authors by number of shared publications:
- Francesca Bonifazi
13IRCCS Azienda Ospedaliero- Universitaria di Bologna, Istituto di Ematologia Seràgnoli, Bologna, Italy
27 shared publications - Giovanni Grillo
15Department of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
27 shared publications - Massimo Martino
Hematology and Stem Cell Transplantation and Cellular Rerapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano “Bianchi-Melacrino-Morelli”, Presidio Morelli, 89121 Reggio Calabria, Italy
27 shared publications - Stefania Bramanti
Istituto Clinico Humanitas, Milano, Italy
26 shared publications - Alice Di Rocco
Hematology, Department of Translational and Precision Medicine, University Sapienza, Rome, Italy
25 shared publications - Anna Dodero
Division of Hematology and Stem Cell Transplantation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. 2
25 shared publications
Latest Publications
- 24 November 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (22) , 7771-7774
A curative-intent treatment program in older AML: mature posttransplant results from the VEN-DEC GITMO study
- 24 November 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (22) , 7771-7774
A curative-intent treatment program in older AML: mature posttransplant results from the VEN-DEC GITMO study
- Open Access
- 14 November 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (11)
Psychosocial Well‐Being in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation and Their Caregivers: A Prospective Study
Although allogeneic hematopoietic stem cell transplantation (allo‐HSCT) offers curative potential for several hematologic malignancies, it is associated with a substantial psychological burden. However, prospective studies simultaneously evaluating psychological distress, quality of life, unmet needs, caregiver strain, and baseline psychosocial vulnerability remain limited. We therefore conducted a prospective single‐center observational study of 115 adult allo‐HSCT recipients assessed peri‐transplant (T0), and at 6 (T1) and 12 (T2) months. Thirty‐two caregivers provided at least one Family Strain Questionnaire—Short Form response, and 31 completed all items required for score calculation. The Psychosocial Assessment of Candidates for Transplantation (PACT) was available for 80 patients and was analyzed exploratorily because the Italian version has not undergone formal psychometric validation. Scores were generally favorable (median score: 38), with only nine patients classified as having low psychosocial suitability (PACT score ≤ 29). Clinically relevant distress (Distress Thermometer ≥ 4) was observed in 67.5%, 69.7%, and 47.4% of patients with valid data at T0, T1, and T2, respectively. Psychological Distress Inventory scores were higher at 6 months than at T0; the 12‐month estimate was numerically lower than at 6 months, but neither the T1–T2 nor the T0–T2 contrast was statistically significant. Informational and communication needs remained frequent, while several SF‐36 domains worsened at 6 months and improved at 12 months. Mean caregiver strain score did not change significantly over time; however, more than half of assessed caregivers were classified in areas indicating that psychological support was strongly recommended or urgent at each time point. These findings indicate distinct psychosocial trajectories among participants and support the potential value of repeated multidimensional psychosocial assessment during the first year after allo‐HSCT.
- 14 November 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (11)
Open AccessPsychosocial Well‐Being in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation and Their Caregivers: A Prospective Study
Although allogeneic hematopoietic stem cell transplantation (allo‐HSCT) offers curative potential for several hematologic malignancies, it is associated with a substantial psychological burden. However, prospective studies simultaneously evaluating psychological distress, quality of life, unmet needs, caregiver strain, and baseline psychosocial vulnerability remain limited. We therefore conducted a prospective single‐center observational study of 115 adult allo‐HSCT recipients assessed peri‐transplant (T0), and at 6 (T1) and 12 (T2) months. Thirty‐two caregivers provided at least one Family Strain Questionnaire—Short Form response, and 31 completed all items required for score calculation. The Psychosocial Assessment of Candidates for Transplantation (PACT) was available for 80 patients and was analyzed exploratorily because the Italian version has not undergone formal psychometric validation. Scores were generally favorable (median score: 38), with only nine patients classified as having low psychosocial suitability (PACT score ≤ 29). Clinically relevant distress (Distress Thermometer ≥ 4) was observed in 67.5%, 69.7%, and 47.4% of patients with valid data at T0, T1, and T2, respectively. Psychological Distress Inventory scores were higher at 6 months than at T0; the 12‐month estimate was numerically lower than at 6 months, but neither the T1–T2 nor the T0–T2 contrast was statistically significant. Informational and communication needs remained frequent, while several SF‐36 domains worsened at 6 months and improved at 12 months. Mean caregiver strain score did not change significantly over time; however, more than half of assessed caregivers were classified in areas indicating that psychological support was strongly recommended or urgent at each time point. These findings indicate distinct psychosocial trajectories among participants and support the potential value of repeated multidimensional psychosocial assessment during the first year after allo‐HSCT.
- 8 July 2026
- Published by Springer Nature
- p. 319-323
Establishing a Data-Driven Upper Bound for CAR-T Prognosis: Quantifying the Impact of Heuristic Discretization
- 8 July 2026
- Published by Springer Nature
- p. 319-323
Establishing a Data-Driven Upper Bound for CAR-T Prognosis: Quantifying the Impact of Heuristic Discretization
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas
Supplementary Figure 2 – Overall survival tisa-cel vs axi-cel in bridging failure
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas
Supplementary Figure 2 – Overall survival tisa-cel vs axi-cel in bridging failure
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas
Supplementary Table 5 – List of centers and patients enrolled
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas
Supplementary Table 5 – List of centers and patients enrolled
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas
Supplementary Table 3 – Summary of real-world data
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas
Supplementary Table 3 – Summary of real-world data
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas
Supplementary Table 1 – Baseline variables associated with ORR at day 90, CRR at day 90, PFS, and OS
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas
Supplementary Table 1 – Baseline variables associated with ORR at day 90, CRR at day 90, PFS, and OS
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas
Supplementary Table 2 – Bivariable Cox model CAR-HEMATOTOX in tisa-cel and axi-cel
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas
Supplementary Table 2 – Bivariable Cox model CAR-HEMATOTOX in tisa-cel and axi-cel
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas
Supplementary Table 4 – Detailed eligibility criteria in accordance with AIFA (Agenzia Italiana Farmaco)
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas
Supplementary Table 4 – Detailed eligibility criteria in accordance with AIFA (Agenzia Italiana Farmaco)
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas
Supplementary figure 3 – Outcomes according to bridging therapy
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas
Supplementary figure 3 – Outcomes according to bridging therapy